Development and validation of an RNAi screen for ABT-737 sensitizers

References

• Green DR, Evan GI. A matter of life and death. Cancer Cell. 2002;1(1):19–30.
   PubMed Web of Science ®Google Scholar
• Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116(2):205–219.
   PubMed Web of Science ®Google Scholar
• Levine B. Eating oneself and uninvited guests: autophagy-related pathways in cellular defense. Cell. 2005;120(2):159–162.
   PubMed Web of Science ®Google Scholar
• Reed JC. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol. 2006;3(7):388–398.
   Google Scholar
• O’Reilly LA, Strasser A. Apoptosis and autoimmune disease. Inflamm Res. 1999;48(1):5–21.
   Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.
   PubMed Web of Science ®Google Scholar
• Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene. 2008;27(50):6398–6406.
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell. 2010;37(3):299–310.
   PubMed Web of Science ®Google Scholar
• Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47–59.
   PubMed Web of Science ®Google Scholar
• Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell. 1985;41(3):899–906.
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A. 1986;83(14):5214–5218.
   PubMed Web of Science ®Google Scholar
• Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335(6189):440–442.
   PubMed Web of Science ®Google Scholar
• Reed JC, Cuddy M, Slabiak T, Croce CM, Nowell PC. Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature. 1988;336(6196):259–261.
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905.
   PubMed Web of Science ®Google Scholar
• Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005;102(39):13944–13949.
   PubMed Web of Science ®Google Scholar
• Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993;82(6):1820–1828.
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303(5660):1010–1014.
   PubMed Web of Science ®Google Scholar
• Fesik SW Insights into programmed cell death through structural biology. Cell. 2000;103(2):273–282.
   Web of Science ®Google Scholar
• Reed JC, Stein C, Subasinghe C, et al. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. 1990;50(20):6565–6570.
   PubMed Web of Science ®Google Scholar
• Schimmer AD, Hedley DW, Chow S, et al. The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2. Cell Death Differ. 2001;8(7):725–733.
   Web of Science ®Google Scholar
• Yip KW, Godoi PH, Zhai D, et al. A TR3/Nur77 peptide-based high-throughput fluorescence polarization screen for small molecule Bcl-B inhibitors. J Biomol Screen. 2008;13(7):665–673.
   Google Scholar
• Walensky LD, Kung AL, Escher I, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science. 2004;305(5689):1466–1470.
   PubMed Web of Science ®Google Scholar
• Yip KW, Li A, Li JH, et al. Potential utility of BimS as a novel apoptotic therapeutic molecule. Mol Ther. 2004;10(3):533–544.
   Web of Science ®Google Scholar
• Yip KW, Mocanu JD, Au PY, et al. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res. 2005;11(22):8131–8144.
   Web of Science ®Google Scholar
• Leone M, Zhai D, Sareth S, Kitada S, Reed JC, Pellecchia M. Cancer prevention by tea polyphenols is linked to their direct inhibition of anti-apoptotic Bcl-2-family proteins. Cancer Res. 2003;63(23):8118–8121.
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677–681.
   PubMed Web of Science ®Google Scholar
• Wang JL, Liu D, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A. 2000;97(13):7124–7129.
   PubMed Web of Science ®Google Scholar
• Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem. 2003;46(20):4259–4264.
   PubMed Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bio-available Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421–3428.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10(5):375–388.
   PubMed Web of Science ®Google Scholar
• Hann CL, Daniel VC, Sugar EA, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008;68(7):2321–2328.
   PubMed Web of Science ®Google Scholar
• High LM, Szymanska B, Wilczynska-Kalak U, et al. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol. 2010;77(3):483–494.
   Web of Science ®Google Scholar
• Trudel S, Stewart AK, Li Z, et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res. 2007;13(2 Pt 1):621–629.
   PubMed Web of Science ®Google Scholar
• Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood. 2010;115(16):3304–3313.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999;4(2):67–73.
   PubMed Web of Science ®Google Scholar
• Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010;9(1):57–67.
   PubMed Web of Science ®Google Scholar
• Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol. 2007;8(1):23–36.
   PubMed Web of Science ®Google Scholar
• Bartz S, Jackson AL. How will RNAi facilitate drug development? Sci STKE. 2005(295):pe39.
   Google Scholar
• Ma Y, Creanga A, Lum L, Beachy PA. Prevalence of off-target effects in Drosophila RNA interference screens. Nature. 2006;443(7109):359–363.
   Web of Science ®Google Scholar
• Lin X, Morgan-Lappe S, Huang X, et al. ‘Seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene. 2007;26(27):3972–3979.
   Web of Science ®Google Scholar
• Sudbery I, Enright AJ, Fraser AG, Dunham I. Systematic analysis of off-target effects in an RNAi screen reveals microRNAs affecting sensitivity to TRAIL-induced apoptosis. BMC Genomics. 2010;11(1):175.
   Google Scholar
• Fedorov Y, Anderson EM, Birmingham A, et al. Off-target effects by siRNA can induce toxic phenotype. RNA. 2006;12(7):1188–1196.
   PubMed Web of Science ®Google Scholar
• Rines DR, Gomez-Ferreria MA, Zhou Y, et al. Whole genome functional analysis identifies novel components required for mitotic spindle integrity in human cells. Genome Biol. 2008;9(2):R44.
   Web of Science ®Google Scholar
• Konig R, Stertz S, Zhou Y, et al. Human host factors required for influenza virus replication. Nature. 2010;463(7282):813–817.
   PubMed Web of Science ®Google Scholar
• Jackson AL, Burchard J, Leake D, et al. Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing. RNA. 2006;12(7):1197–1205.
   PubMed Web of Science ®Google Scholar